Source: Annual Congress 2009 - Cystic fibrosis: advances in clinical research
Disease area: Respiratory infections

Abstract

Background: The macrolide antibiotic azithromycin has anti-inflammatory properties potentially benefitial in cystic fibrosis patients.
Objectives:The purpose of our study was to show effect of 6-month long treatment with azithromycin on clinical status of CF patients.Another aim was to demonstrate improvement of lung function during this treatment.
Design: 30 CF patients colonised by Pseudomonas aeruginosa were included. One group of 15 patients received azithromycin 250/500mg three times a week for 6 months. The second was control group. Groups were matched as far as possible for age, clinical status and lung function. After 6 months we compared clinical status (body mass index (BMI), sputum microbiology, acute exacerbations and Chrispin-Norman chest radiograph score) and lung function between the groups.
Methods:Clinical status was evaluated monthly.Standard CF treatments were continued.Acute exacerbations were treated by iv antibiotics.
Results:Sputum microbiology was unchanged in both groups at the end of treatment. Increase in BMI was noted in the macrolide treated group (p<0,05).Increase in Chrispin-Norman score was registered in the second group (p<0,01).The frequency of pulmonary exacerbations was significantly lower in the azithromycin treated group (0,47 vs. 1,27; p<0,01).Pulmonary function improved in the first group: increase of FEV1, MMEF75/25, MEF50, MEF25 (p<0,01) and decrease of sRtot, ITGV and TLC (p<0,01) were registered.
Conclusions:Our data suggest that long term oral azithromycin treatment is associated with improvements in clinical status and lung function parameters of CF patients.

Rating:

Share or cite this content

Citations should be made in the following way:
A. Vracaric, P. Minic (Uzice, Belgrade, Republic Of Serbia). Effect of long term treatment with azithromycin on clinical status and lung function parameters in cystic fibrosis patients colonised by pseudomonas aeruginosa. Eur Respir J 2009; 34: Suppl. 53, 1268

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of low-dose, long-term clarithromycin administration in improving the clinical course in cystic fibrosis patients with chronic P. aeruginosa airway colonization Source: Eur Respir J 2003; 22: Suppl. 45, 514s Year: 2003 Pseudomonas aeruginosa in patients with cystic fibrosis - a comparison of early eradication and conventional therapy Source: Eur Respir J 2004; 24: Suppl. 48, 385s Year: 2004 Epidemiological-molecular study of colonization by pseudomonas aeruginosa in cystic fibrosis patients Source: Eur Respir J 2002; 20: Suppl. 38, 379s Year: 2002 The clinical impact of nebulised antibiotics in adults with bronchiectasis and chronic pseudomonas aeruginosa Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020 Daily versus weekly azithromycin in cystic fibrosis patients Source: Eur Respir J 2007; 30: 487-495 Year: 2007 Azithromycin in chronic respiratory infections with pseudomonas aeruginosa in patients without cystic fibrosis Source: Annual Congress 2008 - Mechanisms of respiratory infections: interaction between the pathogen and the host Year: 2008 The efficacy of early eradication therapy in prevention of chronic pseudomonas aeruginosa infection in cystic fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 486s Year: 2006 Evaluating the Leeds criteria for Pseudomonas aeruginosa infection in a cystic fibrosis centre Source: Eur Respir J 2006; 27: 937-943 Year: 2006 Chronic but not intermittent infection with Pseudomonas aeruginosa is associated with global changes of the lung microbiome in cystic fibrosis Source: Eur Respir J, 50 (4) 1701086; 10.1183/13993003.01086-2017 Year: 2017 Highly concentrated aerosolized tobramycin in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection Source: Eur Respir J 2005; 26: Suppl. 49, 620s Year: 2005 Long-term evaluation of the response to aggressive treatment at the first colonization of P.aeruginosa in cystic fibrosis (CF) Source: Eur Respir J 2001; 18: Suppl. 33, 126s Year: 2001 Omics-based tracking of Pseudomonas aeruginosa persistence in “eradicated” cystic fibrosis patients Source: Eur Respir J, 57 (4) 2000512; 10.1183/13993003.00512-2020 Year: 2021 Burkholderia cepacia infection in adult cystic fibrosis patients: Its impact on lung function and survival Source: Annual Congress 2010 - New aspects of cystic fibrosis Year: 2010 Usefulness of long term treatment with azithromycin in patients with bronchiectasis (non cystic fibrosis) Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections Year: 2010 Efficacy of ciprofloxacin against resistant mucoid or non-mucoid P. aeruginosa isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis}, Source: Eur Respir J 2012; 40: 1014-1023 Year: 2012 Bacterial infection and lung function in patients with cystic fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 615s Year: 2005 Effects of long-term azithromycin treatment in patients with non-cystic fibrosis stable bronchiectasis Source: Annual Congress 2007 - Infectious lung and pleural diseases Year: 2007 Influence of the lung microbiome on antibiotic susceptibility of cystic fibrosis pathogens Source: Eur Respir Rev, 28 (152) 190041; 10.1183/16000617.0041-2019 Year: 2019 The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis Source: Eur Respir J, 51 (2) 1701953; 10.1183/13993003.01953-2017 Year: 2018